Defining disease stability in COPD: Evidence from Phase 3 clinical trials - PubMed
3 hours ago
- #Disease Stability
- #COPD
- #Clinical Trials
- Defining COPD disease stability as a composite endpoint: no moderate/severe exacerbations, no worsening in CAT and FEV1 from baseline.
- Evidence from Phase 3 trials: Stability achieved in 22-46% of patients with triple therapy vs duals, and 18% with mepolizumab add-on.
- Achieving stability predicts better outcomes: 45.7% reduction in exacerbation risk and 51.7% reduction in mortality risk after Week 28.
- Bayesian joint modeling estimated a 25.60% posterior probability of achieving stability at Week 52 with triple therapy.
- Conclusions: Disease stability is an achievable COPD treatment target that predicts long-term benefits in exacerbations and mortality.